Genedrive PLC Board changes (0533M)
2023年9月11日 - 10:17PM
RNSを含む英国規制内ニュース (英語)
TIDMGDR
RNS Number : 0533M
Genedrive PLC
11 September 2023
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY
GENEDRIVE PLC TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER
THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF
UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018
("MAR").
UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE
INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
genedrive plc
("genedrive" or the "Company")
Board changes
genedrive plc (AIM: GDR), the near patient molecular diagnostics
company announces the appointment of James Cheek as Chief Executive
Officer ("CEO") and a Director of the Company. James will take up
the positions today and will succeed David Budd, who has notified
the Company of his intention to step down from the role with
immediate effect.
James brings extensive commercial and operational experience at
a senior level through a successful career with established
diagnostic companies such as Cepheid, Beckman Coulter, and Roche
Diagnostics, as well as serving as an executive board member of the
British In Vitro Diagnostics Association (BIVDA). The Board
believes James' experience, especially his extensive involvement in
selling into the NHS, will be valuable as the Company expands its
commercial footprint and opportunities within the UK and more
widely.
We are also pleased to announce the appointment of Dr Gino
Miele, Chief Scientific Officer at genedrive, to the Board as an
Executive Director, with immediate effect. Gino has considerable
experience in the development of molecular diagnostic technologies
and systems and has been the R&D Director at genedrive since
2015 and its predecessor Epistem since 2011. Prior to that Gino has
held associate director positions in personalised medicine at Wyeth
and Pfizer. Gino has been a key driver in the development of the
genedrive(R) system and the recent menu of pharmacogenetic
tests.
Ian Gilham, Chairman of genedrive, commented: "I am pleased to
welcome James to the Company and look forward to working with him
on the continued execution of our plans in commercialising our
innovative Point-of-Care molecular diagnostic platform and tests.
The focus of the Board remains on the development and
commercialisation of novel Point-of-Care Molecular Diagnostic
opportunities available to the Company. James' appointment
underlines the Board's commitment to the ongoing successful
commercial execution of the Company's innovative portfolio. I would
also like to welcome Gino to the Board and look forward to his
ongoing contributions to the Company going forwards.
"I would also like to thank David for his dedication and
leadership over the past seven years, as he transitioned the
Company from a Contract Research Organisation to being an innovator
in the development of molecular diagnostics for use at
Point-of-Care. David has agreed to support James as required during
his transition into his new role."
James Cheek, incoming CEO of genedrive commented: "I am very
pleased to be joining genedrive at such a pivotal time for the
launch and commercialisation of new rapid Point-of-Care
pharmacogenetic tests for antibiotic induced hearing loss in
children and optimal treatment selection for stroke patients on the
genedrive(R) platform. I look forward to working with the
outstanding individuals at genedrive, to deliver solutions that our
customers need."
The following information is disclosed pursuant to Schedule Two,
paragraph (g) of the AIM Rules for Companies in respect of James
Cheek:
Full name and age: James Bernard Cheek (aged 56)
James Cheek does not currently hold any ordinary shares in
genedrive plc.
Current Directorships or Partnerships:
None
Past Directorships of Partnerships:
Cepheid UK Limited
The British In Vitro Diagnostics Association (BIVDA)
No further information in connection with James Cheek's
appointment is required to be disclosed under Schedule Two,
paragraph (g) of the Aim Rules for Companies.
The following information is disclosed pursuant to Schedule Two,
paragraph (g) of the AIM Rules for Companies in respect of Dr. Gino
Miele:
Full name and age: Dr. Gino Miele (aged 53)
Gino Miele and his wife hold 66,979 ordinary shares in genedrive
plc.
Current Directorships or Partnerships:
Cytomos Limited
Past Directorships of Partnerships:
GMDX Limited
No further information in connection with Dr. Gino Miele's
appointment is required to be disclosed under Schedule Two,
paragraph (g) of the Aim Rules for Companies.
For further details please contact:
genedrive plc +44 (0)161 989 0245
Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser
and Joint Broker) +44 (0)20 7418 8900
James Steel / Patrick Birkholm
finnCap (Joint Broker) +44 (0)20 7220 0500
Geoff Nash
Walbrook PR Ltd (Media & Investor +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Relations)
+44 (0)7980 541 893 / +44
Paul McManus / Anna Dunphy (0)7876 741 001
About genedrive plc ( http://www.genedriveplc.com )
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for use in
patient stratification (genotyping), pathogen detection and other
indications in emergency care.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABXGDCUBBDGXB
(END) Dow Jones Newswires
September 11, 2023 09:17 ET (13:17 GMT)
Genedrive (LSE:GDR)
過去 株価チャート
から 4 2024 まで 5 2024
Genedrive (LSE:GDR)
過去 株価チャート
から 5 2023 まで 5 2024